|Day Low/High||16.17 / 17.23|
|52 Wk Low/High||5.65 / 20.50|
Stockholders Asked to Approve Issuance of Common Stock in Connection with Acquisition by Ventrus of Assembly Pharmaceuticals, Inc.
General Cable, Theravance and Ventrus Biosciences are our big swing trades for today. So how should investors buy and sell?
Ventrus Biosciences (VTUS) surged Thursday despite a lack of significant news on the company in much the same way other biotech stocks Prana Biotechnology (PRAN) and DARA Biosciences (DARA) had risen earlier in the week.
Ventrus Biosciences (VTUS) plunged to a one-year low of 85 cents on Monday after the company agreed to merge with Assembly Pharmaceuticals in an all-stock transaction.
These stocks look ready to break out and trade higher from current levels.
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Results Expected First Quarter 2014; NDA Filing Expected to Occur in Second Quarter 2014
Results From Second Pivotal Phase 3 Trial in Anal Fissures Expected First Quarter 2014
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Ventrus Biosciences, Inc.
Compounded Formulations From Retail Pharmacies Are Inaccurate in Respect to Potency Approximately 50% of the Time and Lack Content Uniformity Approximately 40% of the Time
These stocks look poised to break out and trade higher from current levels.
Holzer Holzer & Fistel, LLC is investigating whether Ventrus Biosciences, Inc.
Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.